SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - PURE Bioscience, Inc. (
Research Instruments has completed extensive testing of PURE's SDC-based products as a unique and novel disinfectant, safe for use in the fertility market, where the benefits include:
- Safe for use in the presence of human sperm, eggs and embryos
- High efficacy with low contact times
- No VOC (volatile organic compound) content
- No cross contamination potential
- Long product shelf life
Research Instruments obtained EU marketing approval under EU Medical Device Directive 93/42/EEC and will market the SDC-based technology under its private label Fertisafe Plus™.
"This licensing agreement is part of PURE's strategy to out-license our SDC-based products into non-core markets (outside the food safety arena) with established businesses who have the demonstrative marketing and distribution capabilities in their respective markets," said Peter C. Wulff, CFO and COO of PURE. "While the economics of this license agreement are modest, it serves as an important medical device technology endorsement of SDC. Broadening the use of SDC as a disinfectant in this unique medical device market for assisted reproduction facilities demonstrates the critical non-toxic and safe attributes of SDC for pathogen and microbe control in such sensitive environments."
Research Instruments introduced Fertisafe Plus™ at the annual European Society of Human Reproduction and Embryology (ESHRE) meeting in Munich, Germany in July, generating considerable interest. "We were exceptionally pleased with the response from our international market," commented Bill Brown, Managing Director of Research Instruments. "The labs we work with have very demanding requirements given the importance of their work. Fertisafe Plus™ ticks all of their boxes for safety, efficacy, speed and certification."
About Fertisafe Plus™
Fertisafe Plus™ is a unique embryo-safe and sperm safe SDC-based disinfectant. CE Marked as a Medical Device, Fertisafe Plus offers long lasting, ready to use, broad-spectrum antimicrobial protection to the reproductive arts industry. Quaternary ammonium free and odorless, it is proven to kill bacteria, viruses and fungi on work areas and lab equipment between procedures, yet is embryo and sperm safe. Fertisafe Plus™ is MEA and HSSA batch tested to give complete safety confidence.
About Research Instruments Limited
Privately owned Research Instruments is based in Cornwall, United Kingdom. Research Instruments Limited has been in business for over 50 years. Specializing in leading edge technology and medical devices for the fertility field, RI has become the company of choice when looking for the latest in biomedical technology. RI's philosophy of Success through Innovation permeates the organization resulting in a comprehensive product portfolio offering the latest developments in technology to its customer base. For more information about Research Instruments Limited, please visit www.research-instruments.com.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control primarily in the food safety arena. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
- Health Care Industry
Redwood Investment Group
VP of IR
Bibicoff + MacInnis, Inc.
Peter C. Wulff
CFO & COO
Research Instruments Ltd.
+44 (0)1326 372753